Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel

References

• Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227–276
   PubMed Web of Science ®Google Scholar
• Warden BA, Willman AM, Williams CD. Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke. Nat Rev Neurol 2012;8:223–235
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J M 2009;360:354–362
   PubMed Web of Science ®Google Scholar
• Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv 2011;4:422–428
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a meta-analysis. JAMA 2010;304:1821–1830
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) investigators: Genetic determinations of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363–375
   PubMed Web of Science ®Google Scholar
• Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011;4:585–594
   PubMed Web of Science ®Google Scholar
• Jia DM1, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, Zhang CL, Shao Y, Chen C, Xu Y. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 2013;44:1717–1719
   PubMed Web of Science ®Google Scholar
• Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 2011;90:328–332
   PubMed Web of Science ®Google Scholar
• Liu X, Xu G, Wu W, Zhang R, Yin Q, Zhu W. Subtypes and one-year survival of first-ever stroke in Chinese patients: The Nanjing stroke registry. Cerebrovascular Dis 2006;22:130–136
   PubMed Web of Science ®Google Scholar
• Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, Li Z, You L, Zhao J, Liu J. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat genet 2010;43:55–59
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–1598
   PubMed Web of Science ®Google Scholar
• Anonymous. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673–682
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Tomasello SD, Capodanno D, Desai B, Dharmashankar K, Seecheran N, Kodali MK, Darlington A, Pham JP, et al. Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: Results of a prospective, randomized, crossover study. Circ Cardiovasc Interv 2011;4:273–279
   PubMed Web of Science ®Google Scholar
• Fernando H, Dart AM, Peter K, Shaw JA. Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. Thromb Haemost 2011;105:933–944
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) Study. J Am Coll Cardiol 2008;51:256–260
   PubMed Web of Science ®Google Scholar
• De Morais S, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of s-mephenytoin metabolism in humans. J Bio Chem 1994;269:15419–15422
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84:236–242
   PubMed Web of Science ®Google Scholar
• Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? The role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation 2012;125:1288–1303
   PubMedGoogle Scholar
• Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–858
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Buettner HJ, Neumann FJ. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010;55:2427–2434
   PubMed Web of Science ®Google Scholar
• Sibbing D, Bernlochner I, Kastrati A, Pare G, Eikelboom JW. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ Cardiovasc Interv 2011;4:505–513
   PubMed Web of Science ®Google Scholar
• Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by maldi-tof mass spectrometry in Chinese Han population. Forensic Sci Int 2011;207:183–187
   PubMed Web of Science ®Google Scholar